Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study

Thrombosis and Haemostasis

Volumn 118, Issue 4, 2018, Pages 639-646

  Ruffatti, Amelia ^a   Tonello, Marta ^a   Hoxha, Ariela ^a   Sciascia, Savino ^b   Cuadrado, Maria J ^b   Latino, José O ^c   Udry, Sebastian ^c   Reshetnyak, Tatiana ^d   Costedoat Chalumeau, Nathalie ^e,f,g   Morel, Nathalie ^e,f   Marozio, Luca ^h   Tincani, Angela ⁱ   Andreoli, Laura ⁱ   Haladyj, Ewa ^j   Meroni, Pier L ^k,l,m   Gerosa, Maria ^k,l,m   Alijotas Reig, Jaume ^n,o   Tenti, Sara ^p   Mayer Pickel, Karoline ^q   Simchen, Michal J ^r   Bertero, Maria T ^s   De Carolis, Sara ^t   Ramoni, Véronique ^u   Mekinian, Arsène ^v   Grandone, Elvira ^w   Maina, Aldo ^x   Serrano, Fátima ^y   Pengo, Vittorio ^a   Khamashta, Munther A ^b,z   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c HOSPITAL DURAND   (Argentina)

^d V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^e Centre de Référence Maladies Auto immunes et Systémiques Rares ^*  (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g PARIS DESCARTES UNIVERSITY   (France)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j NATIONAL INSTITUTE OF GERIATRICS   (Poland)

^k G Pini Orthopaedic Institute   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

^m ISTITUTO AUXOLOGICO ITALIANO   (Italy)

ⁿ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^o UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^p UNIVERSITY OF SIENA   (Italy)

^q MEDICAL UNIVERSITY OF GRAZ   (Austria)

^r SHEBA MEDICAL CENTER   (Israel)

^s Clinical Immunology   (Italy)

^t CATHOLIC UNIVERSITY   (Italy)

^u FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^v HÔPITAL SAINT ANTOINE   (France)

^w CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^x UO di Elettrofisiologia   (Italy)

^y NOVA MEDICAL SCHOOL   (Portugal)

^z DUBAI HOSPITAL   (United Arab Emirates)

more..

Author keywords

antiphospholipid syndrome; hydroxychloroquine; intravenous immunoglobulins; low dose steroids; plasma exchange

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; PREDNISONE; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; STEROID;

ADOLESCENT; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS DEATH; HUMAN; INFANTILE SPASM; LIVE BIRTH; LUNG SEQUESTRATION; MAJOR CLINICAL STUDY; PLASMA EXCHANGE; PREGNANCY; PREGNANCY COMPLICATION; PREGNANT WOMAN; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPONTANEOUS ABORTION; THROMBOSIS; BIRTH RATE; BLOOD; CLINICAL TRIAL; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PREGNANCY OUTCOME; RISK;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BIRTH RATE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULINS, INTRAVENOUS; LIVE BIRTH; LUPUS COAGULATION INHIBITOR; PLASMA EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RETROSPECTIVE STUDIES; RISK; STEROIDS; THROMBOSIS;

EID: 85042793183     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1632388     Document Type: Article

References (32)

1. Lassere M. Empson M. Treatment of antiphospholipid syndrome in pregnancy - a systematic review of randomized therapeutic trials. Thromb Res: 2004; 114 (5-6): 419 426
2. Sailer T. Zoghlami C. Kurz C., et al. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost: 2006; 95 05 796 801
3. Fischer-Betz R. Specker C. Brinks R. Schneider M. Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. Lupus: 2012; 21 11 1183 1189
4. Matsuki Y. Atsumi T. Yamaguchi K., et al. Clinical features and pregnancy outcome in antiphospholipid syndrome patients with history of severe pregnancy complications. Mod Rheumatol: 2015; 25 02 215 218
5. Ruffatti A. Tonello M. Del Ross T., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost: 2006; 96 03 337 341
6. Ruffatti A. Tonello M. Cavazzana A. Bagatella P. Pengo V. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholipid syndrome prescribed antithrombotic therapy. Thromb Res: 2009; 123 03 482 487
7. Ruffatti A. Tonello M. Visentin M. S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford): 2011; 50 09 1684 1689
8. Latino J. O. Udry S. Aranda F. M. Perés Wingeyer S. DA. Fernández Romero D. S. de Larrañaga G. F. Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile. Lupus: 2017; 26 09 983 988
9. Lockshin M. D. Kim M. Laskin C. A., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum: 2012; 64 07 2311 2318
10. Nodler J. Moolamalla S. R. Ledger E. M. Nuwayhid B. S. Mulla Z. D. Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset. BMC Pregnancy Childbirth: 2009; 9 11
11. Simchen M. J. Dulitzki M. Rofe G., et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand: 2011; 90 12 1428 1433
12. Lima F. Khamashta M. A. Buchanan N. M. Kerslake S. Hunt B. J. Hughes G. R. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol: 1996; 14 02 131 136
13. Bramham K. Hunt B. J. Germain S., et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus: 2010; 19 01 58 64
14. de Jesús G. R. Rodrigues G. de Jesús N. R. Levy R. A. Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? Curr Rheumatol Rep: 2014; 16 02 403
15. Bowman Z. S. Wünsche V. Porter T. F. Silver R. M. Branch D. W. Prevalence of antiphospholipid antibodies and risk of subsequent adverse obstetric outcomes in women with prior pregnancy loss. J Reprod Immunol: 2015; 107 59 63
16. Danowski A. de Azevedo M. N. de Souza Papi J. A. Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol: 2009; 36 06 1195 1199
17. Ruffatti A. Hoxha A. Favaro M., et al. Additional treatments for high-risk obstetric antiphospholipid syndrome: a comprehensive review. Clin Rev Allergy Immunol: 2017; 53 01 28 39
18. Ruffatti A. Salvan E. Del Ross T., et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost: 2014; 112 04 727 735
19. Miyakis S. Lockshin M. D. Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 02 295 306
20. Tincani A. Allegri F. Balestrieri G., et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res: 2004; 114 (5-6): 553 558
21. Reber G. Tincani A. Sanmarco M. de Moerloose P. Boffa M. C.; Standardization Group of the European Forum on Antiphospholipid Antibodies. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost: 2004; 2 10 1860 1862
22. Brandt J. T. Triplett D. A. Alving B. Scharrer I. Criteria for the diagnosis of lupus anticoagulant. Thromb Haemost: 1995; 74 04 1185 1190
23. Pengo V. Tripodi A. Reber G., et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost: 2009; 7 10 1737 1740
24. Mekinian A. Lazzaroni M. G. Kuzenko A., et al. SNFMI and the European Forum on Antiphospholipid Antibodies. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. Autoimmun Rev: 2015; 14 06 498 502
25. Sciascia S. Hunt B. J. Talavera-Garcia E. Lliso G. Khamashta M. A. Cuadrado M. J. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol: 2016; 214 02 273.e1 273.e8
26. Kaplan Y. C. Ozsarfati J. Nickel C. Koren G. Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol: 2016; 81 05 835 848
27. Cherin P. Marie I. Michallet M., et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev: 2016; 15 01 71 81
28. El-Haieg D. O. Zanati M. F. El-Foual F. M. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet: 2007; 99 03 236 241
29. Ruffatti A. Favaro M. Hoxha A., et al. Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A prospective study. J Reprod Immunol: 2016; 115 14 19
30. Reber G. Tincani A. Sanmarco M. de Moerloose P. Boffa M. C.; European Forum on Antiphospholipid Antibodies Standardization Group. Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays. Thromb Haemost: 2005; 94 03 665 672
31. Pengo V. Biasiolo A. Bison E. Chantarangkul V. Tripodi A.; Italian Federation of Anticoagulation Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb Res: 2007; 120 01 127 133
32. Favaloro E. J. Wheatland L. Jovanovich S. Roberts-Thomson P. Wong R. C. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part I - Anticardiolipin and anti-β2-glycoprotein I antibodies. Semin Thromb Hemost: 2012; 38 04 390 403